Didn't find the company you were looking for? Our full system contains all Danish companies, including comprehensive credit risk reports. Register here to get started.
You can find text and video tutorials here that explain how to use our system.
REPONEX PHARMACEUTICALS A/S
CVR number: 30082346
Slotsmarken 18, 2970 Hørsholm
www.reponex.dk
Income statement (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | |||||
| Costs of management | -5 780.00 | -7 517.00 | |||
| Employee benefit expenses | - 119.44 | ||||
| Other operating expenses | -1 827.86 | -2 144.99 | -12 603.84 | -5 497.00 | -9 083.00 |
| Total depreciation | - 390.35 | - 157.04 | |||
| EBIT | -2 337.66 | -2 302.03 | -12 603.84 | -11 277.00 | -16 600.00 |
| Other financial income | 0.16 | 0.03 | 66.00 | ||
| Other financial expenses | -21.49 | -80.78 | - 250.77 | -22.00 | -45.00 |
| Pre-tax profit | -2 358.99 | -2 382.81 | -12 854.58 | -11 299.00 | -16 579.00 |
| Income taxes | 505.07 | 877.91 | 2 971.42 | 1 855.00 | 2 233.00 |
| Net earnings | -1 853.92 | -1 504.90 | -9 883.16 | -9 444.00 | -14 346.00 |
Assets (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible rights | 12 267.91 | 16 960.39 | 13 355.59 | 13 860.00 | 13 598.00 |
| Intangible assets total | 12 267.91 | 16 960.39 | 13 355.59 | 13 860.00 | 13 598.00 |
| Other tangible assets | 10.73 | 5.36 | 320.54 | 582.00 | 55.00 |
| Tangible assets total | 10.73 | 5.36 | 320.54 | 582.00 | 55.00 |
| Other non-current investments | 452.00 | ||||
| Investments total | 452.00 | ||||
| Long term receivables total | |||||
| Inventories total | 883.34 | 1 040.01 | 1 160.86 | ||
| Current owed by particip. interest comp. | 1 416.00 | ||||
| Prepayments and accrued income | 203.54 | 216.03 | 22.56 | 1 587.00 | 423.00 |
| Current other receivables | 633.79 | 865.37 | 961.90 | 802.00 | 1 547.00 |
| Current deferred tax assets | 964.51 | 1 185.95 | 1 483.48 | 1 855.00 | 2 233.00 |
| Short term receivables total | 1 801.84 | 2 267.35 | 2 467.94 | 4 244.00 | 5 619.00 |
| Cash and bank deposits | 2 537.91 | 135.75 | 11 403.25 | 2 830.00 | 1 938.00 |
| Cash and cash equivalents | 2 537.91 | 135.75 | 11 403.25 | 2 830.00 | 1 938.00 |
| Balance sheet total (assets) | 17 501.73 | 20 408.87 | 28 708.18 | 21 516.00 | 21 662.00 |
Equity and liabilities (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 602.27 | 602.27 | 829.54 | 830.00 | 850.00 |
| Share premium account | 20 861.39 | 20 861.39 | |||
| Other reserves | 8 610.41 | 12 423.97 | 9 958.68 | 18 081.00 | 15 907.00 |
| Retained earnings | -13 286.80 | -18 954.29 | 26 466.17 | 9 444.00 | 14 346.00 |
| Profit of the financial year | -1 853.92 | -1 504.90 | -9 883.16 | -9 444.00 | -14 346.00 |
| Shareholders equity total | 14 933.34 | 13 428.44 | 27 371.23 | 18 911.00 | 16 757.00 |
| Non-current leasing loans | 162.64 | 295.00 | 234.00 | ||
| Provisions | 1 179.90 | 1 487.94 | |||
| Non-current other liabilities | -1 179.90 | -2 975.88 | |||
| Non-current deferred tax liabilities | 1 179.90 | 1 487.94 | |||
| Non-current liabilities total | 1 179.90 | 162.64 | 295.00 | 234.00 | |
| Current leasing loans | 286.00 | 217.00 | |||
| Current trade creditors | 1 193.93 | 1 858.21 | 745.68 | 1 606.00 | 2 659.00 |
| Other non-interest bearing current liabilities | 194.56 | 3 634.28 | 428.62 | 418.00 | 1 795.00 |
| Current liabilities total | 1 388.49 | 5 492.49 | 1 174.30 | 2 310.00 | 4 671.00 |
| Balance sheet total (liabilities) | 17 501.73 | 18 920.93 | 28 708.17 | 21 516.00 | 21 662.00 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
... and more!
No registration needed.